This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Organoids study discovers promising treatment for deadly uterine cancer

New treatment for deadly uterine cancer
a Schematic diagram illustrating the principle of PLA assay and autocrine loop mode of activation in carcinoma cells with FGFR2c splice isoform expression (I); In situ indirect PLA assay design, with one primary antibody omitted (technical negative control) without signal formation (II) and positive signal formation with incubation of both primary antibodies (III). b Representative images of PLA assay in ASPDX67_CL primary EC cell line grown in DMEM/F12 with 10% FBS or 16 hr of serum starvation (0.5% FBS) followed by stimulation with and without 10 ng/ml FGF2 + 0.01% DMSO for 30 min (top panels) or 300 nM BGJ398 (bottom panels). Credit: npj Precision Oncology (2023). DOI: 10.1038/s41698-023-00478-6

QUT scientists have discovered a promising new therapy for a deadly type of endometrial cancer that has a poor prognosis if the cancer spreads or returns after initial treatment, a plight that affects 15%–20% of endometrial cancer patients.

Dr. Asmerom Sengal and Associate Professor Pamela Pollock from QUT's School of Biomedical Sciences, published their research, "Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition," in npj Precision Oncology with a recommendation that the strength of their findings indicated they should proceed to patient trials.

Dr. Asmerom said endometrial cancer confined within the uterus could be cured with surgery however, if it had spread to the abdomen and other organs patients had limited treatment options.

"Previously, we found women with endometrial cancer who have an incorrect growth factor receptor called fibroblast growth factor receptor 2c (FGFR2c) on the tumor cell surface have a poor survival rate," Dr. Asmerom said.

"For this study, we developed organoids—three-dimensional miniature tumors grown from patients' endometrial in a hydrogel to enable us to study the complexity of the tumor structure and genetics.

"We found that endometrial cancer organoids with activated (or turned on) FGFR2c were blocked with an FGFR inhibitor drug and the organoids' growth was shattered and they died.

"These findings were further validated by blocking of 'turned-on' FGFR2c in patient-derived xenografts (PDXs)—endometrial cancers implanted in mice—with the same FGFR2c inhibitor which resulted in significant tumor growth inhibition, and the treated mice showed a remarkable increase in survival.

Dr. Asmerom said an interesting finding was that the endometrial cancer patient xenografts which harbored activated FGFR2c were treated with FGFR inhibitor for seven days and demonstrated remarkable reduction in tumor blood vessel formation and the (M2-macrophages) that prevent our immune system from killing cancer cells.

"Collectively, the study supports the initiation of a clinical trial combining a FGFR inhibitor with immunotherapy and this opens a new opportunity for personalized care in women with deadly ," he said.

More information: Asmerom T. Sengal et al, Endometrial cancer PDX-derived organoids (PDXOs) and PDXs with FGFR2c isoform expression are sensitive to FGFR inhibition, npj Precision Oncology (2023). DOI: 10.1038/s41698-023-00478-6

Journal information: npj Precision Oncology
Citation: Organoids study discovers promising treatment for deadly uterine cancer (2023, December 13) retrieved 17 July 2024 from https://medicalxpress.com/news/2023-12-organoids-treatment-deadly-uterine-cancer.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

New biomarker for poor prognosis endometrial cancer

0 shares

Feedback to editors